


FORM 1449*



INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION

(Use several sheets if necessary)

RECEIVED
AUG 6 2002
TECH CENTER 6800/2600

Docket Number D0136NP/30436.58USU1	Application Number 10/057,288
Applicant Christian P. Larsen et al.	
Filing Date January 25, 2002	Group Art Unit 16404

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
[Signature]	4,603,102 (Exhibit 1)	07/29/86	Himmelman et al.			06/26/85
	5,430,057 (Exhibit 2)	07/04/95	Andersson et al.			09/30/93
	5,434,131 (Exhibit 3)	07/18/95	Linsley et al.			05/26/93
	5,559,148 (Exhibit 4)	09/24/96	Andersson et al.			05/24/95
	5,637,481 (Exhibit 5)	06/10/97	Ledbetter et al.			09/13/93
	5,773,253 (Exhibit 6)	06/30/98	Linsley et al.			07/21/95
	5,844,095 (Exhibit 7)	12/01/98	Linsley et al.			01/18/95
	5,851,795 (Exhibit 8)	12/22/98	Linsley et al.			06/02/95
	5,876,692 (Exhibit 9)	03/02/99	Ildstad			01/17/97
	5,885,579 (Exhibit 10)	03/23/99	Linsley et al.			07/08/97
	5,885,796 (Exhibit 11)	03/23/99	Linsley et al.			06/05/95
	6,090,914 (Exhibit 12)	07/18/00	Linsley et al.			04/15/94
	6,113,898 (Exhibit 13)	09/05/00	Anderson et al.			06/07/95
	6,217,867 B1 (Exhibit 14)	04/17/01	Ildstad			10/22/98

FOREIGN PATENT DOCUMENTS

DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
WO96/23071 (Exhibit 15)	08/01/96	PCT				X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

[Signature]	Abrams, Judith R. et al., "Blockade of T Lymphocyte Costimulation with Cytotoxic T Lymphocyte-associated Antigen 4-Immunoglobulin (CTLA4Ig) Reverse the Cellular Pathology of Psoriatic plaques, Including the Activation of Keratinocytes, Dendritic Cells, and Endothelial Cells, " <i>Journal of Experimental Medicine</i> , 2000, 192:681-693 (Exhibit 16)
	Adams, Andrew B. et al., "Costimulation Blockade, Busulfan, and Bone Marrow Promote Titratable Macrochimerism, Induce Transplantation Tolerance, and Correct Genetic Hemoglobinopathies with Minimal Myelosuppression," <i>Journal of Immunology</i> , 2001, 167:1103-11 (Exhibit 17)
	Ahmed, Rafi et al., "Selection of Genetic Variants of Lymphocytic Choriomeningitis Virus in Spleens of Persistently Infected Mice," <i>Journal of Experimental Medicine</i> , 1984, 160:521-40 (Exhibit 18)

EXAMINER

[Signature]


DATE CONSIDERED

2/14/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


FORM 1449*  INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number D0136NP/30436.58USU1	Application Number 10/057,288
	Applicant Christian P. Larsen et al.	
	Filing Date January 25, 2002	Group Art Unit 1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
No		Andreasen, Susanne Ørding et al., "Surface marker abnormalities in myelodysplastic syndromes," <i>Journal of Immunology</i> , 2000, 164:3689-97 (Exhibit 19)
		Aruffo, S., Presentation of "Approaches to Immune Regulation" at BIO 2000 in Boston, Massachusetts, March 27, 2000 (Exhibit 20)
		Basch, Ross S. et al., "Growth of Human Hematopoietic Cells in Immunodeficient Mice Conditioned with Cyclophosphamide and Busulfan," <i>Stem Cells</i> , 1997, 15:314-23 (Exhibit 21)
		Becker, J.C., Abstract and Presentation of "A multi-center, randomized, double-blind, placebo controlled study to evaluate the safety and preliminary clinical activity of multiple doses of CTLA4Ig and LEA29Y administration intravenously to subjects with rheumatoid arthritis," presented at American College of Rheumatology Conference: "2001 Innovative Therapies in Autoimmune Diseases," San Francisco, California, March 8, 2001 (Exhibit 22)
		Bervers, Edouard M. et al., "Transmembrane Phospholipid Distribution in Blood Cells: Control Mechanisms and Pathophysiological Significance," <i>Biological Chemistry</i> , 1998, 379:973-86 (Exhibit 23)
		Bill, Jerome et al., "The MHC Molecule I-E is Necessary but not Sufficient for the Clonal Deletion of VB11-Bearing T Cells," <i>Journal of Experimental Medicine</i> , 1989, 169:1405-19 (Exhibit 24)
		Billingham, R. E. et al., "'Actively Acquired Tolerance' of Foreign Cells," <i>Nature</i> , 1953, 172:603-6 (Exhibit 25)
		Bratton, Donna L. et al., "Appearance of Phosphatidylserine on Apoptotic Cells Requires Calcium-mediated Nonspecific Flip-Flop and Is Enhanced by Loss of the Aminophospholipid Translocase," <i>Journal of Biological Chemistry</i> , 1997, 272:26159-65 (Exhibit 26)
		Brodsky, Isadore et al., "The Role of Busulfan/Cyclophosphamide Regimens in Allogeneic and Autologous Bone Marrow Transplant," <i>Cancer Investigation</i> , 1989, 7:509-13 (Exhibit 27)
		Butz, Eric A. and Michael J. Bevan, "Massive Expansion of Antigen-Specific CD8 ⁺ T Cells during an Acute Virus Infection," <i>Immunity</i> , 1998, 8:167-75 (Exhibit 28)
		Byrn, Randal A. et al., "Characterization of In Vitro Inhibition of Human Immunodeficiency Virus by Purified Recombinant CD4," <i>Journal of Virology</i> , 1989, 63:4370-5 (Exhibit 29)
		Champlin, Richard et al., "Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy," <i>Current Opinion in Oncology</i> , 1999, 11:87-95 (Exhibit 30)
		Christian, John A. et al., "Methodologic considerations for the use of canine in vivo aged biotinylated erythrocytes to study RBC senescence," <i>Experimental Hematology</i> , 1996, 24:82-8 (Exhibit 31)
		Closse, Christèle et al., "Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium," <i>British Journal of Hematology</i> , 1999, 107:300-2 (Exhibit 32)
		Craddock, Charles, "Nonmyeloablative stem cell transplants," <i>Current Opinion in Hematology</i> , 1999, 6:383-7 (Exhibit 33)
A		Dariavach, Piona et al., "Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains," <i>European Journal of Immunology</i> , 1988, 18:1901-5 (Exhibit 34)


EXAMINER <i>P. M. P. G. M. A. R.</i>	DATE CONSIDERED <i>2/18/05</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FORM 1449* 	INFORMATION DISCLOSURE STATEMENT	
	IN AN APPLICATION	
	(Use several sheets if necessary)	
	Docket Number D0136NP/30436.58USU1	Application Number 10/057,288
Applicant Christian P. Larsen et al.		
Filing Date January 25, 2002	Group Art Unit 1646	


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Dash, Bret et al., "Deletion of a single N-linked glycosylation site from the transmembrane envelope protein of human immunodeficiency virus type 1 stops cleavage and transport of gp160 preventing env-mediated fusion," <i>Journal of General Virology</i> , 1994, 75:1389-97 (Exhibit 35)
		Durham, Megan M. et al., "Cutting Edge: Administration of Anti-CD40 Ligand and Donor Bone Marrow Leads to Hemopoietic Chimerism and Donor-Specific Tolerance Without Cytoablative Conditioning," <i>Journal of Immunology</i> , 2000, 165:1-4 (Exhibit 36)
		Dyson, P. J. et al., "Genes encoding ligands for deletion of Vβ11 T cells cosegregate with mammary tumour virus genomes," <i>Nature</i> , 1991, 349:531-2 (Exhibit 37)
		Falk, Kirsten et al., "Both Human and Mouse Cells Expressing H-2K ^b and Ovalbumin Process the Same Peptide, SIINFEKL," <i>Cellular Immunology</i> , 1993, 150:447-52 (Exhibit 38)
		Flesher, Alan R., Presentation of 'Transgenic Production, A Comparative Study' at Bio 99 in Seattle, Washington, April 15, 1999 (Exhibit 39)
		Frasch, S. Courtney et al., "Regulation of Phospholipid Scramblase Activity during Apoptosis and Cell Activation by Protein Kinase Cδ," <i>Journal of Biological Chemistry</i> , 2000, 275:23065-73 (Exhibit 40)
		Fujikawa, Kiyomi et al., "Short Communications: Nuclear Localization and Transforming Activity of Human Papillomavirus Type 16 E7-β-Galactosidase Fusion Protein: Characterization of the Nuclear Localization Sequence," <i>Virology</i> , 1994, 204:789-93 (Exhibit 41)
		Gandhi, Rajesh B. et al., Abstract and Presentation of "Physical and Chemical Characterization of BMS-224818, A Recombinant Fusion Protein," in San Francisco, California, <i>PharmSci Supplement</i> , November 18, 1998, 1:S-535 (Exhibit 42)
		Gérard, C. et al., "Production and Characterization of Polyclonal Antibodies Recognizing the Intracytoplasmic Third Loop of the 5-Hydroxytryptamine Receptor," <i>Neuroscience</i> , 1994, 62:721-39 (Exhibit 43)
		Greene, JoAnne L. et al., "Covalent Dimerization of CD28/CTLA-4 and Oligomerization of CD80/CD86 Regulate T Cell Costimulatory Interactions," <i>Journal of Biological Chemistry</i> , 1996, 271:26762-71 (Exhibit 44)
		Greve, Kimberly F., "Capillary electrophoretic examination of underivatized oligosaccharide mixtures released from immunoglobulin G antibodies and CTLA4lg fusion protein," <i>Journal of Chromatography</i> , 1996, 749:237-245 (Exhibit 45)
		Handschumacher, Robert E., "Immunosuppressive Agents," <i>Goodman and Gilman's: The Pharmacological Basis of Therapeutics</i> , Pergamon Press, NY, 1990, 1264-76 (Exhibit 46)
		Hansen, John A. et al., "Monoclonal Antibodies Identifying a Novel T-Cell Antigen and Ia Antigens of Human Lymphocytes," <i>Immunogenetics</i> , 1980, 10:247-60 (Exhibit 47)
		Hathcock, Karen S. et al., "Identification of an Alternative CTLA-4 Ligand Costimulatory for T Cell Activation," <i>Science</i> , 1993, 262:905-911 (Exhibit 48)
		Honey, Karen et al., "CD40 Ligand Blockade Induces CD4 ⁺ T Cell Tolerance and Linked Suppression," <i>Journal of Immunology</i> , 1999, 163:4805-10 (Exhibit 49)
		Ikeda, Toshio et al., "Isolation of a cDNA encoding the chicken p508/p97 (Lyt-10) transcription factor," <i>Gene</i> , 1994, 138:193-6 (Exhibit 50)

EXAMINER P. H. W. Gaudin 2/14/05	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FORM 1449*		Docket Number D0136NP/30436.58USU1	Application Number 10/057,288
 <p>INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</p> <p>(Use several sheets if necessary)</p>		Applicant Christian P. Larsen et al.	
		Filing Date January 25, 2002	Group Art Unit 1644


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

M		Ildstad, Suzanne T. and David H. Sachs, "Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts," <i>Nature</i> , 1984, 307:168-70 (Exhibit 51)
		Johnsson, Bo et al., "Immobilization of Proteins to a Carboxymethyldextran-Modified Gold Surface for Biospecific Interaction Analysis in Surface Plasmon Resonance Sensors," <i>Analytical Biochemistry</i> , 1991, 198:268-77 (Exhibit 52)
		Joneckis, Christopher C. et al., "Integrin $\alpha\beta_1$ and Glycoprotein IV (CD36 Are Expressed on Circulating Reticulocytes in Sickle Cell Anemia," <i>Blood</i> , 1993, 82:3548-55 (Exhibit 53)
		Jones, Nancy H. et al., "Isolation of complementary DNA clones encoding the human lymphocyte glycoprotein T1/Leu-1," <i>Nature</i> , 1986, 323:346-9 (Exhibit 54)
		Khilko, Sergei N. et al., "Direct Detection of Major Histocompatibility Complex Class I Binding to Antigenic Peptides Using Surface Plasmon Resonance," <i>Journal of Biological Chemistry</i> , 1993, 268:15425-34 (Exhibit 55)
		Knoerzer, Debbie Barney et al., "Collagen-induced Arthritis in the BB Rat: Prevention of Disease by Treatment with CTLA-4-Ig," <i>Journal of Clinical Investigation</i> , 1995, 96:987-93 (Exhibit 56)
		Kolhekar, Aparna S. et al., "Peptidylglycine α -Hydroxylating Monooxygenase: Active Site Residues, Disulfide Linkages, and a Two-Domain Model of the Catalytic Core," <i>Biochemistry</i> , 1997, 36:10901-9 (Exhibit 57)
		Krishnamurti, Lashsmanan et al., "Bone Marrow Transplantation without Myeloablation for Sickle Cell Disease," <i>New England Journal of Medicine</i> , 2001, 344:68 (Exhibit 58)
		Kuypers, Frans A. et al., "Detection of Altered Membrane Phospholipid Asymmetry in Subpopulations of Human Red Blood Cells Using Fluorescently Labeled Annexin V," <i>Blood</i> , 1996, 87:1179-87 (Exhibit 59)
		Larsen, Christian P., Presentation of "Costimulation blockade: Progress toward clinical application" at the American Society of Transplantation Meeting in Las Croabas, Puerto Rico, Jan. 13-17, 2000 (Exhibit 60)
		Larsen, Christian P., Presentation of "Costimulation blockade: progress toward clinical application" at Canadian Society of Transplantation Annual Scientific meeting in Mont Tremblant, Quebec, Canada, March 3-4, 2000 (Exhibit 61)
		Larsen, Christian P. et al., Abstract of "Prolongation of Renal Allograft Survival with Blockade of the CD28 Pathway Using A Novel Mutant CTLA4-IG Fusion Protein In Non-Human Primates," in <i>Transplantation</i> , 2000, 69:S123, #45 (Exhibit 62)
		Larsen, Christian P. et al., Presentation of "Prolongation of Renal Allograft Survival With Blockade of the CD28 Pathway Using A Novel Mutant CTLA4-Ig Protein In Nonhuman Primates" at the American Society of Transplantation Meeting in Chicago, Illinois, March 3-4, 2000 (Exhibit 63)
		Larsen, Christian P., Presentation of "Manipulation of Costimulatory Pathways: Targeting CD80 and CD86" at the XVII congress of the Transplantation Society in Rome, Italy, Aug. 27-Sept.1, 2000 (Exhibit 64)
		Lasky, Laurence A. et al., "Neutralization of the AIDS Retrovirus by Antibodies to a Recombinant Envelope Glycoprotein," <i>Science</i> , 1986, 233:209-12 (Exhibit 65)

EXAMINER Philip Gabor	DATE CONSIDERED 2/14/05
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FORM 1449* 	Docket Number	Application Number
	D0136NP/30436.58USU1	10/057,288
	Applicant	
	Christian P. Larsen et al.	
Filing Date		Group Art Unit
January 25, 2002		16467


(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
M		Lenz, Laurel L. et al., "Requirements for Bone Marrow-derived Antigen-presenting Cells in Priming Cytotoxic T Cell Responses to Intracellular Pathogens," <i>Journal of Experimental Medicine</i> , 2000, 192:1135-42 (Exhibit 66)
		Linsley, Peter S. et al., "Coexpression and Functional Cooperation of CTLA-4 and CD28 on Activated T Lymphocytes," <i>Journal of Experimental Medicine</i> , 1992, 176:1595-604 (Exhibit 67)
		Linsley, Peter S. et al., "Human B7-1 (CD80) and B7-2 (CD86) Bind with Similar Avidities but Distinct Kinetics to CD28 and CTLA-4 Receptors," <i>Immunity</i> , 1994, 1:793-801 (Exhibit 68)
		Linsley, Peter S. et al., "Binding Stoichiometry of the Cytotoxic T Lymphocyte-associated Molecule-4 (CTLA-4)," <i>Journal of Biological Chemistry</i> , 1995, 270:15417-24 (Exhibit 69)
		Lucarelli, G. et al., "Marrow Transplantation for Thalassemia after Treatment with Busulfan and Cyclophosphamide," <i>Annals New York Academy of Sciences</i> , 1985, 445:428-31 (Exhibit 70)
		Lyons, A. Bruce and Christopher R. Parish, "Determination of lymphocyte division by flow cytometry," <i>Journal of Immunological Methods</i> , 1994, 171:131-7 (Exhibit 71)
		Maini, Ravinder et al., "Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial," <i>The Lancet</i> , 1999, 354:1932-9 (Exhibit 72)
		Malik, Najma et al., "Molecular Cloning, Sequence Analysis, and Functional Expression of a Novel Growth Regulator, Oncostatin M," <i>Molecular and Cellular Biology</i> , 1989, 9:2847-53 (Exhibit 73)
		Markees, Thomas G. et al., "Long-Term Survival of Skin Allografts Induced by Donor Splenocytes and Anti-CD154 Antibody in Thymectomized Mice Requires CD4 ⁺ T Cells, Interferon- γ , and CTLA4," <i>Journal of Clinical Investigation</i> , 1998, 101:2446-55 (Exhibit 74)
		Martin, Paul J. et al., "Preincubation of Donor Bone Marrow Cells with a Combination of Murine Monoclonal Anti-T-Cell Antibodies Without Complement Does Not Prevent Graft-Versus-Host Disease After Allogeneic Marrow Transplantation," <i>Journal of Clinical Immunology</i> , 1984, 4:18-22 (Exhibit 75)
		Mathiesen, T. et al., "Prolonged survival and vascularization of xenografted human glioblastoma cells in the central nervous system of Cyclosporine A treated rats," <i>Cancer Letters</i> , 1989, 44:151-6 (Exhibit 76)
		Mayumi, Hisanori and Robert A. Good, "Long-Lasting Skin Allograft Tolerance in Adult Mice Induced Across Fully Allogeneic (Multimajor H-2 Plus Multiminor Histocompatibility) Antigen Barriers by a Tolerance-Inducing Method Using Cyclophosphamide," <i>Journal of Experimental Medicine</i> , 1989, 169:213-38 (Exhibit 77)
		Mentzer, William C. and Morton J. Cowan, "Bone Marrow Transplantation for β -Thalassemia: The University of California San Francisco Experience," <i>Journal of Pediatric Hematology/Oncology</i> , 2000, 22:598-601 (Exhibit 78)
		Metzler, William J. et al., "Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28," <i>Nature Structural Biology</i> , 1997, 4:527-31 (Exhibit 79)
		Moreland, Larry W. et al., "Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial," <i>Annals of Internal Medicine</i> , 1999, 130:478-86 (Exhibit 80)
		Murali-Krishna, Kaja et al., "Counting Antigen-Specific CD8 T Cells: A Reevaluation of Bystander Activation during Viral Infection," <i>Immunity</i> , 1998, 8:177-87 (Exhibit 81)

EXAMINER	DATE CONSIDERED
<i>Phenol G 10/05</i>	2/14/05
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FORM 1449* 	INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)		Docket Number	Application Number	
			D0136NP/30436.58USU1	10/057,288	
	Applicant			Group Art Unit	
	Christian P. Larsen et al.			1646	
			Filing Date		
			January 25, 2002		


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

M		Murali-Krishna and Rafi Ahmed, "Cutting Edge: Naive T Cells Masquerading as Memory Cells," <i>Journal of Immunology</i> , 2000, 165:1733-7 (Exhibit 82)
		O'Shannessy, Daniel J. et al., "Determination of Rate and Equilibrium Binding Constants for Macromolecular Interactions Using Surface Plasmon Resonance: Use of Nonlinear Least Squares Analysis Methods," <i>Analytical Biochemistry</i> , 1993, 212:457-68 (Exhibit 83)
		Oaks, Martin K. et al., "A Native Soluble Form of CTLA-4," <i>Cellular Immunology</i> , 2000, 201:144-53 (Exhibit 84)
		Owen, Ray D., "Immunogenetic Consequences of Vascular Anastomoses between bovine twins," <i>Science</i> , 1945, 102:400-1 (Exhibit 85)
		Pászty, Chris et al., "Transgenic Knockout Mice with Exclusively Human Sickle Hemoglobin and Sickle Cell Disease," <i>Science</i> , 1997, 278:876-8 (Exhibit 86)
		Peach, Robert J. et al., "Complementarity Determining Region 1 (CDR-1)- and CDR3-analogous Regions in CTLA-4 and CD28 Determine the Binding to B7-1," <i>Journal of Experimental Medicine</i> , 1994, 180:2049-58 (Exhibit 87)
		Pearson, Thomas C. et al., "CTLA4-Ig Plus Bone Marrow Induces Long-Term Allograft Survival and Donor-Specific Unresponsiveness in the Murine Model," <i>Transplantation</i> , 1996, 61:997-1004 (Exhibit 88)
		Pichlmayr, R. et al., "Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection," <i>The Lancet</i> , 1995, 345:1321-5 (Exhibit 89)
		Platt, Orah S. and Eva C. Guinan, "Bone Marrow Transplantation in Sickle Cell Anemia - The Dilemma of Choice," <i>New England Journal of Medicine</i> , 1996, 335:426-8 (Exhibit 90)
		Ruedl, Christiane et al., "Phenotypic and functional characterization of CD11c ⁺ dendritic cell population in mouse Peyer's patches," <i>European Journal of Immunology</i> , 1996, 26:1801-6 (Exhibit 91)
		Salomon, Benoit and Jeffrey A. Bluestone, "Complexities of CD28/B7: CTLA-4 Costimulatory Pathways in Autoimmunity and Transplantation," <i>Annual Review of Immunology</i> , 2001, 19:225-52 (Exhibit 92)
		Santos, G. W. et al., "HLA-Identical Marrow Transplants in Aplastic Anemia, Acute Leukemia, and Lymphosarcoma Employing Cyclophosphamide," <i>Human Bone Marrow Transplantation</i> , 1976, 63-9 (Exhibit 93)
		Sayegh, Mohamed H. et al., "Donor Antigen is Necessary for the Prevention of Chronic Rejection in CTLA4-Ig-Treated Murine Cardiac Allograft Recipients," <i>Transplantation</i> , 1997, 64:1646-50 (Exhibit 94)
		Serke, Stefan and Dieter Huhn, "Identification of CD71 (transferring receptor) expressing erythrocytes by multiparameter-flow-cytometry (MP-FCM): correlation to the quantitation of reticulocytes as determined by conventional microscopy and by MP-FCM using a RNA-staining dye," <i>British Journal of Hematology</i> , 1992, 81:432-9 (Exhibit 95)
		Sfikakis, Peter P. et al., "CD28 Expression On T Cell Subsets In Vivo and CD28-Mediated T Cell Response In Vitro in Patients with Rheumatoid Arthritis," <i>Arthritis & Rheumatism</i> , 1995, 38:649-54 (Exhibit 96)


EXAMINER	<i>P. H. G. Amos</i>	DATE CONSIDERED	2/14/05
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			


*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FORM 1449* 	Docket Number	Application Number
	DO136NP/30436.58USU1	10/057,288
	Applicant	
	Christian P. Larsen et al.	
Filing Date		Group Art Unit
January 25, 2002		1646


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


	Shahinian, Arda et al., "Differential T Cell Costimulatory Requirements in CD28-Deficient Mice," <i>Science</i> , 1993, 261:609-12 (Exhibit 97)
	Sharabi, Yedida and David H. Sachs, "Mixed Chimerism and Permanent Specific Transplantation Tolerance Induced by a Nonlethal Preparative Regimen," <i>Journal of Experimental Medicine</i> , 1989, 169:493-502 (Exhibit 98)
	Shehee, W. Ronald et al., "Lethal thalassemia after insertional disruption of the mouse major adult β -globin gene," <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90:3177-81 (Exhibit 99)
	Slavin, Shimon et al., "Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation with Lethal Cytoablation for the Treatment of Malignant and Nonmalignant Hematologic Diseases," <i>Blood</i> , 1998, 91:756-63 (Exhibit 100)
	Smith, Douglas H. et al., "Blocking of HIV-1 Infectivity by a Soluble, Secreted Form of the CD4 Antigen," <i>Science</i> , 1987, 238:1704-7 (Exhibit 101)
	Spitzer, Thomas R. et al., "Intentional Induction of Mixed Chimerism and Achievement of Antitumor Responses After Nonmyeloablative Conditioning Therapy and HLA-Matched Donor Bone Marrow Transplantation for Refractory Hematologic Malignancies," <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6:309-20 (Exhibit 102)
	Srinivas, N. R. et al., "Pharmacokinetics and Pharmacodynamics of CTLA4Ig (BMS-188667), a Novel Immunosuppressive Agent, in Monkeys following Multiple Doses," <i>Journal of Pharmaceutical Sciences</i> , 1996, 85:1-4 (Exhibit 103)
	Srinivas, Nuggehally R. et al., "Assessment of Dose Proportionality, Absolute Bioavailability, and Immunogenicity Response of CTLA4Ig (BMS-188667), a Novel Immunosuppressive Agent, Following Subcutaneous and Intravenous Administration to Rats," <i>Pharmaceutical Research</i> , 1997, 14:911-6 (Exhibit 104)
	Swerlick, Robert A. et al., " $\alpha\beta_1$ -Integrin Expression on Sickie Reticulocytes: Vascular Cell Adhesion Molecule-1-Dependent Binding to Endothelium," <i>Blood</i> , 1993, 82:1891-9 (Exhibit 105)
	Sykes, Megan et al., "Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning," <i>Nature Medicine</i> , 1997, 3:783-7 (Exhibit 106)
	Thomas, E. Donnall et al., "Marrow Transplantation for Thalassemia," <i>The Lancet</i> , 1982, 2:227-9 (Exhibit 107)
	Tomita, Yukihiro et al., "Myelosuppressive Condition Is Required to Achieve Engraftment of Pluripotent Stem Cells Contained in Moderate Doses of Syngeneic Bone Marrow," <i>Blood</i> , 1994, 83:939-48 (Exhibit 108)
	Tomita, Yukihiro et al., "Role of Intrathymic Clonal Deletion and Peripheral Anergy in Transplantation Tolerance Induced by Bone Marrow Transplantation in Mice Conditioned with a Nonmyeloablative Regimen," <i>Journal of Immunology</i> , 1994, 153:1087-98 (Exhibit 109)
	Turgeon, Nicole A. et al., "Viral Infection Abrogates CD8 ⁺ T-cell Deletion Induced by Costimulation Blockade," <i>Journal of Surgical Research</i> , 2000, 93:63-9 (Exhibit 110)
	Urlaub, Gail et al., "Effect of Gamma Rays at the Dihydrofolate Reductase Locus: Deletions and Inversions," <i>Somatic Cell and Molecular Genetics</i> , 1986, 12:555-66 (Exhibit 111)



EXAMINER	DATE CONSIDERED
	2/14/05
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FORM 1449*  INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	RECEIVED AUG 06 2002 TECH CENTER 1600/2800	
	Docket Number	Application Number
	DO136NP/30436.58USU1	10/057,288
	Applicant	
Christian P. Larsen et al.		
Filing Date	Group Art Unit	
January 25, 2002	1644	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Vermes, István et al., "A novel assay for apoptosis Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V," <i>Journal of Immunological Methods</i> , 1995, 184:39-51 (Exhibit 112)
		Vermeylen, C. et al., "Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium," <i>Bone Marrow Transplantation</i> , 1998, 22:1-6 (Exhibit 113)
		Walters, Mark C. et al., "Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report," <i>Blood</i> , 2000, 95:1918-24 (Exhibit 114)
		Warner, G. L. et al., Abstract and Presentation of "Bioactivity of BMS-188667 (CTLA4lg) in Cynomolgus Monkeys," in Seattle, Washington, March 16-22, 1995 (Exhibit 115)
		Webb, Louise M. C. et al., "Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2" <i>European Journal of Immunology</i> , 1996, 26:2320-8 (Exhibit 116)
		Weinblatt, Michael E. et al., "A Trial of Etanercept, A Recombinant Tumor Necrosis Factor Receptor: Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate," <i>New England Journal of Medicine</i> , 1999, 340:253-9 (Exhibit 117)
		Weiner, R. et al., Abstract and Presentation of "Validation and PK Application of a Double Antibody Sandwich Enzyme Immunoassay For the Quantitation of Human CTLA4lg Fusion Protein (BMS-188667) in Mouse Serum," November 6-10, 1994 (Exhibit 118)
		Weiner, Russell et al., Abstract and Presentation of "Validation of an Enzyme Immunoassay for the Quantitation of Human CTLA4lg Fusion Protein in Human Serum," in Miami, Florida, November 1995 (Exhibit 119)
		Weiner, Russell, Abstract and Presentation of "Automation and Validation of An EIA For Quantitation of Human CTLA4lg in Monkey Serum," in Miami, Florida, November 1995 (Exhibit 120)
		Weiner, Russell S. et al., "A sensitive enzyme immunoassay for the quantitation of human CTLA4lg fusion protein in mouse serum: pharmacokinetic application to optimizing cell line selection," <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1997, 15:571-579 (Exhibit 121)
		Weiner, Russell S., Abstract and Presentation of "Industrial Perspectives of Primary Analytical Tools for Macromolecules- Principles and Applications with Examples" March 1, 2000 (Exhibit 122)
		Wekerle, Thomas et al., "Extrathymic T Cell Deletion and Allogeneic Stem Cell Engraftment Induced with Costimulatory Blockade Is Followed by Central T Cell Tolerance," <i>Journal of Experimental Medicine</i> , 1998, 187:2037-44 (Exhibit 123)
		Wekerle, Thomas et al., "Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment," <i>Nature Medicine</i> , 2000, 6:464-9 (Exhibit 124)
		Wells, Andrew D. et al., "Following the Fate of Individual T Cells throughout Activation and Clonal Expansion," <i>Journal of Clinical Investigation</i> , 100:3173-83 (Exhibit 125)
		Welsh, Raymond M. et al., "Virus-Induced Abrogation of Transplantation Tolerance Induced by Donor-Specific Transfusion and Anti-CD154 Antibody," <i>Journal of Virology</i> , 2000, 74:2210-8 (Exhibit 126)
		Whitmire, Jason K. et al., "CD40 Ligand-Deficient Mice Generate a Normal Primary Cytotoxic T-Lymphocyte Response but a Defective Humoral Response to a Viral Infection," <i>Journal of Virology</i> , 1996, 70:8375-81 (Exhibit 127)

EXAMINER		DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			
*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE			

A circular black ink stamp from the Office of the Patent & Trademark Office. The text "OFFICE OF THE" is curved along the top inner edge, and "PATENT & TRADEMARK OFFICE" is curved along the bottom inner edge. In the center, the date "AUG 05 2002" is stamped horizontally.

(Use several sheets if necessary)

D0136NP/30436.58USU1

10/057,288

Christian P. Larsen et al.

January 25, 2002

1646

Whitmore, Jason K. et al., "CD40-CD40 Ligand Costimulation is Required for Generating Antiviral CD4 T Cell Responses But Is Dispensable for CD8 T Cell Responses," <i>Journal of Immunology</i> , 1999, 163:3194-201 (Exhibit 128)
Whitney, J. Barry III, "Simplified Typing of Mouse Hemoglobin (<i>Hbb</i>) Phenotypes Using Cystamine," <i>Biochemical Genetics</i> , 1978, 16:667-72 (Exhibit 129)
Williams, Matthew A. et al., "Genetic Characterization of Strain Differences in the Ability to Mediate CD40/CD28-Independent Rejection of Skin Allografts," <i>Journal of Immunology</i> , 2000, 165:6849-57 (Exhibit 130)
Wood, Brent L. et al., "Increased Erythrocyte Phosphatidylserine Exposure in Sickle Cell Disease: Flow-Cytometric Measurement and Clinical Associations," <i>Blood</i> , 1996, 88:1873-80 (Exhibit 131)
Yang, Hyekyung and Raymond M. Welsh, "Induction of Alloreactive Cytotoxic T Cells by Acute Virus Infection of Mice," <i>Journal of Immunology</i> , 1986, 136:1186-93 (Exhibit 132)
Yang, Hyekyung et al., "Virus-Induced Polyclonal Cytotoxic T Lymphocyte Stimulation," <i>Journal of Immunology</i> , 1989, 142:1710-8 (Exhibit 133)
Yeager, A. M. et al., "Growth retardation and depigmentation of hair after high-dose busulfan and congenic hemtopoietic cell transplantation in mice," <i>Bone Marrow Transplantation</i> , 1992, 9:199-204 (Exhibit 134)
Yokochi, Takashi et al, "B Lymphblast Antigen (BB-1) Expressed on Epste.in-Barr Virus-Activated B Cell Blasts, B Lymphoblastoid Cell Lines, And Burkitt's Lymphomas," <i>Journal of Immunology</i> , 1982, 128:823-7 (Exhibit 135)
Zarozinski, Christopher C. and Raymond M. Welsh, "Minimal Bystander Activation of CD8 T Cells during the Virus-induced Polyclonal T Cell Response," <i>Journal of Experimental Medicine</i> , 1997, 185:1629-39 (Exhibit 136)

RECEIVED
AUG 06 2002
TECH. CENTER 1600/2900


Philip G. Gorman

✓14/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

* Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



RECEIVED

JAN 29 2003

TECH CENTER 1600/2900

Sheet 1 of 5

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number D0136NP/30436.58USU1	Application Number 10/057,288
	Applicant Christian P. Larsen et al.	
	Filing Date January 25, 2002	Group Art Unit 1646

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
u	WO95/33770 (Exhibit 137)	12/14/95	PCT				X
	WO02/02638 A2 (Exhibit 138)	12/14/95	PCT				X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Linsley, Peter S. et al., "CTLA-4 Is a Second Receptor for the B Cell Activation Antigen B7" <i>The Journal of Experimental Medicine</i> , 1991, 174:561-9 (Exhibit 139)
	Gimmi, Claude D. et al., "Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation" <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90:6586-90 (Exhibit 140)
	Azuma, Miyuki et al., "B70 antigen is a second ligand for CTLA-4 and CD28" <i>Nature</i> , 1993, 366:76-9 (Exhibit 141)
	Ronchese, Franca et al., "Mice Transgenic for a Soluble Form of Murine CTLA-4 Show Enhanced Expansion of Antigen-specific CD4 ⁺ T Cells and Defective Antibody Production In Vivo" <i>The Journal of Experimental Medicine</i> , 1994, 179:809-17 (Exhibit 142)
	Griggs, Nathan D. et al., "The Relative Contribution of the CD28 and gp39 Costimulatory Pathways in the Clonal Expansion and Pathogenic Acquisition of Self-reactive T Cells" <i>The Journal of Experimental Medicine</i> , 1996, 183:801-10 (Exhibit 143)
	Verwilghen, Jo et al., "Expression of Functional B7 and CTLA4 on Rheumatoid Synovial T Cells" <i>The Journal of Immunology</i> , 1994, 153:1378-85 (Exhibit 144)
	Blazar, Bruce R. et al., "In Vivo Blockade of CD28/CTLA4: B7/BB1 Interaction With CTLA4-Ig Reduces Lethal Murine Graft-Versus-Host Disease Across the Major Histocompatibility Complex Barrier in Mice" <i>Blood</i> , 1994, 83:3815-25 (Exhibit 145)
	Finck, Barbara K., et al., "Treatment of Murine Lupus with CTLA4Ig" <i>Science</i> , 1994, 265:1225-7 (Exhibit 146)
	Perrin, Peter J. et al., "Role of B7:CD28/CTLA-4 in the Induction of Chronic Relapsing Experimental Allergic Encephalomyelitis" <i>The Journal of Immunology</i> , 1995, 154:1481-90 (Exhibit 147)
	Pearson, Thomas C. et al., "Transplantation Tolerance Induced By CTLA4-Ig" <i>Transplantation</i> , 1994, 57:1701-6 (Exhibit 148)
	Baliga, Prabhakar et al., "CTLA4Ig Prolongs Allograft Survival While Suppressing Cell-Mediated Immunity" <i>Transplantation</i> , 1994, 58:1082-90 (Exhibit 149)
n	Tepper, M. A. et al., "Tolerance Induction by Soluble CTLA4 in a Mouse Skin Transplant Model" <i>Transplantation Proceedings</i> , 1994, 26:3151-4 (Exhibit 150)

EXAMINER 	DATE CONSIDERED 2/14/05
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number D0136NP/30436.58USU1	Application Number 10/057,288
	Applicant Christian P. Larsen et al.	
	Filing Date January 25, 2002	Group Art Unit 1648 <i>f</i>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
<i>24</i>		Perico, Norberto et al., "Toward novel antirejection strategies: <i>In vivo</i> immunosuppressive properties of CTLA4Ig" <i>Kidney International</i> , 1995, 47:241-6 (Exhibit 151)
		Finck, B. K. et al., "Effects of CTLA4Ig in Murine Lupus" <i>Arthritis and Rheumatism</i> , 1994, 37:S222 (Exhibit 152)
		Nishikawa, Kazuhiro et al., "Effect of CTLA-4 chimeric protein on rat autoimmune anti-glomerular basement membrane glomerulonephritis" <i>Eur. J. Immunol.</i> , 1994, 24:1249-54 (Exhibit 153)
		Wallace, Philip M. et al., "CTLA4Ig Treatment Ameliorates the Lethality of Murine Graft-Versus-Host Disease Across Major Histocompatibility Complex Barriers" <i>Transplantation</i> , 1994, 58:602-10 (Exhibit 154)
		Damle, Nitin K. et al., "Costimulation of T Lymphocytes with Integrin Ligands Intercellular Adhesion Molecule-1 or Vascular Cell Adhesion Molecule-1 Induces Functional Expression of CTLA-4, a Second Receptor for B7" <i>The Journal of Immunology</i> , 1994, 152:2686-97 (Exhibit 155)
		Milich, David R. et al., "Soluble CTLA-4 Can Suppress Autoantibody Production and Elicit Long Term Unresponsiveness in a Novel Transgenic Model," <i>The Journal of Immunology</i> , 1994, 153:429-35 (Exhibit 156)
		Van Oosterhout, A. J. M. et al., "Murine CTLA4-IgG Treatment Inhibits Airway Eosinophilia and Hyperresponsiveness and Attenuates IgE Upregulation in a Murine Model of Allergic Asthma," <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1997, 17:386-92 (Exhibit 157)
		Abrams, Judith R. et al., "CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris," <i>The Journal of Clinical Investigation</i> , 1999, 103:1243-52 (Exhibit 158)
		Ibrahim, Sherif et al., "CTLA4Ig Inhibits Alloantibody Responses to Repeated Blood Transfusions," <i>Blood</i> , 1996, 88:4594-600 (Exhibit 159)
		Lenschow, Deborah J. et al., "Differential Effects of Anti-B7-1 and Anti-B7-2 Monoclonal Antibody Treatment on the Development of Diabetes in the Nonobese Diabetic Mouse," <i>J. Exp. Med.</i> , 1995, 181:1145-55 (Exhibit 160)
		Lenschow, Deborah J. et al., "Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4Ig," <i>Science</i> , 1992, 257:789-92 (Exhibit 161)
		Sayegh, Mohamed H., "Finally, CTLA4Ig graduates to the clinic," <i>The Journal of Clinical Investigation</i> , 1999, 103:1223-5 (Exhibit 162)
		Wolfe, Frederick, "The epidemiology of drug treatment failure in rheumatoid arthritis," <i>Baillière's Clinical Rheumatology</i> , 1995, 9:619-32 (Exhibit 163)
		Hochberg, Marc C. and Timothy D. Spector, "Epidemiology of Rheumatoid Arthritis: Update," <i>Epidemiologic Reviews</i> , 1990, 12:247-52 (Exhibit 164)
		Spector, Tim D., "Rheumatoid Arthritis," <i>Rheumatic Disease Clinics of North America</i> , 1990, 16:513-37 (Exhibit 165)
		Liu, Ming Fei, et al., "The Presence of Costimulatory Molecules CD86 and CD28 in Rheumatoid Arthritis Synovium," <i>Arthritis & Rheumatism</i> , 1996, 39:110-4 (Exhibit 166)
		Sfikakis, Petros P. and Charles S. Via, "Expression of CD28, CTLA4, CD80, and CD86 Molecules in Patients with Autoimmune Rheumatic Diseases: Implications for Immunotherapy," <i>Clinical Immunology and Immunopathology</i> , 1997, 83: 195-8 (Exhibit 167)
<i>25</i>		Sayegh, Mohamed H., et al., "CD28-B7 Blockade after Alloantigenic Challenge In Vivo Inhibits Th1 Cytokines but Spares Th2," <i>J. Exp. Med.</i> , 1995, 181: 1869-74 (Exhibit 168)

EXAMINER <i>Phuup GAMBOR</i>	DATE CONSIDERED <i>2/14/05</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	
*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	



FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number D0136NP/30436.58USU1	Application Number 10/057,288
	Applicant Christian P. Larsen et al.	
	Filing Date January 25, 2002	Group Art Unit 16467

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Racusen, Lorraine C., et al., "The Banff 97 working classification of renal allograft pathology," <i>Kidney International</i> , 1999, 55: 713- 23 (Exhibit 169)
		Parkin, David, et al., "Treatment of multiple sclerosis with interferon β : an appraisal of cost-effectiveness and quality of life," <i>J. Neurol. Neurosurg. Psychiatry</i> , 2000, 68:144-9 (Exhibit 170)
		Nortvedt, Monica W. et al., "Quality of life in multiple sclerosis: Measuring the disease effects more broadly," <i>Neurology</i> , 1999, 53:1098-1103 (Exhibit 171)
		Liao, Hua-Xin and Barton F. Haynes, "Role of Adhesion Molecules in the Pathogenesis of Rheumatoid Arthritis," <i>Rheumatic Disease Clinics of North America</i> , 1995, 21:715-40 (Exhibit 172)
		Thomas, Ranjeny and Christopher Quinn, "Functional Differentiation of Dendritic Cells in Rheumatoid Arthritis: Role of CD86 in the Synovium," <i>The Journal of Immunology</i> , 1996, 156:3074-86 (Exhibit 173)
		Verhoeven, A. C. et al., "Combination Therapy in Rheumatoid Arthritis: Updated Systematic Review," <i>British Journal of Rheumatology</i> , 1998, 37:612-9 (Exhibit 174)
		Schiff, Michael, "Emerging Treatments for Rheumatoid Arthritis" <i>Am. J. Med.</i> , 1997, 102: 11S-15S (Exhibit 175)
		Balsa, A. et al., "Differential Expression of the Costimulatory Molecules B7.1 (CD80) and B7.2 (CD86) in Rheumatoid Synovial Tissue," <i>British Journal of Rheumatology</i> , 1996, 35:33-7 (Exhibit 176)
		Ranheim, Erik A. and Thomas J. Kipps, "Elevated Expression of CD80 (B7/BB1) and Other Accessory Molecules on Synovial Fluid Mononuclear Cell Subsets in Rheumatoid Arthritis," <i>Arthritis & Rheumatism</i> , 1994, 37:1637-46 (Exhibit 177)
		Freeman, Gordon J. et al., "Cloning of B7-2: A CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation," <i>Science</i> , 1993, 262:909-11 (Exhibit 178)
		Lakkis, Fadi G. et al., "Blocking the CD28-B7 T Cell Costimulation Pathway Induces Long Term Cardiac Allograft Acceptance in the Absence of IL-4," <i>The Journal of Immunology</i> , 1997, 158:2443-8 (Exhibit 179)
		Pearson, Thomas C. et al., "Analysis of the B7 Costimulatory Pathway in Allograft Rejection," <i>Transplantation</i> , 1997, 63:1463-9 (Exhibit 180)
		Alexander, Diane Z. et al., "Analysis of a Functional Role for Chimerism in CTLA4-Ig Plus Bone Marrow-Treated Cardiac Allograft Recipients," <i>Transplantation</i> , 1994, 91:416-8 (Exhibit 181)
		Larsen, Christian P. et al., "CD40-gp39 Interactions Play a Critical Role During Allograft Rejection," <i>Transplantation</i> , 1996, 61:4-9 (Exhibit 182)
		Pearson, Thomas C. et al., "CTLA4-Ig Plus Bone Marrow Induces Long-Term Allograft Survival and Donor-Specific Unresponsiveness in the Murine Model," <i>Transplantation</i> , 1996, 61:997-1004 (Exhibit 183)
		Weber, C. J. et al., "CTLA4-Ig Prolongs Survival of Microencapsulated Rabbit Islet Xenografts in Spontaneously Diabetic Nod Mice," <i>Transplantation Proceedings</i> , 1996, 28:821-3 (Exhibit 184)
		Alexander, D. Z. et al., "Analysis of effector mechanisms in murine cardiac allograft rejection," <i>Transplant Immunology</i> , 1996, 4:46-8 (Exhibit 185)
		Larsen, Christian P. et al., "Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways," <i>Nature</i> , 1996, 381:434-8 (Exhibit 186)

EXAMINER 	DATE CONSIDERED 4/4/05
---------------------	----------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.


*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number 00136NP/30436.58USU1	Application Number 10/057,288
	Applicant Christian P. Larsen et al.	
	Filing Date January 25, 2002	Group Art Unit 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Ny	Elwood, Eric T. et al., "Microchimerism and rejection in clinical transplantation," <i>The Lancet</i> , 1997, 349:1358-60 (Exhibit 187)
	Larsen, Christian P. and Thomas C. Pearson, "The CD40 pathway in allograft rejection, acceptance, and tolerance," <i>Current Opinion in Immunology</i> , 1997, 9:641-7 (Exhibit 188)
	Konieczny, Bogumila T. et al., "IFN- γ Critical for Long-Term Allograft Survival Induced by Blocking the CD28 and CD40 Ligand T Cell Costimulation Pathways," <i>The Journal of Immunology</i> , 1998, 160:2059-64 (Exhibit 189)
	Elwood, Eric T. et al., "Prolonged Acceptance of Concordant and Discordant Xenografts with Combined CD40 and CD28 Pathway Blockade," <i>Transplantation</i> , 1998, 65:1422-8 (Exhibit 190)
	Nilmi, Masanori et al., "The Role of the CD40 Pathway in Alloantigen-Induced Hyporesponsiveness In Vivo," <i>The Journal of Immunology</i> , 1998, 161:5331-7 (Exhibit 191)
	Bingaman, Adam W. et al., "Vigorous Allograft Rejection in the Absence of Danger," <i>The Journal of Immunology</i> , 2000, 164:3065-71 (Exhibit 192)
	Bingaman, Adam W. et al., "Transplantation of the Bone Marrow Microenvironment Leads to Hematopoietic Chimerism Without Cytoinductive Conditioning," <i>Transplantation</i> , 2000, 69:2491-6 (Exhibit 193)
	Bingaman, Adam W. et al., "The role of CD40L in T cell-dependent nitric oxide production by murine macrophages," <i>Transplant Immunology</i> , 2000, 8:195-202 (Exhibit 194)
	Meng, L. et al., "Blockade of the CD40 Pathway Fails to Prevent CD8 T Cell-Mediated Intestinal Allograft Rejection," <i>Transplantation Proceedings</i> , 2001, 33:418-20 (Exhibit 195)
	Guo, Zhong et al., "CD8 T Cell-Mediated Rejection of Intestinal Allografts is Resistant to Inhibition of the CD40/CD154 Costimulatory Pathway," <i>Transplantation</i> , 2001, 71:1351-4 (Exhibit 196)
	Ha, Jongwon et al., "Aggressive skin allograft rejection in CD28 ^{-/-} mice independent of the CD40/CD40L costimulatory pathway," <i>Transplant Immunology</i> , 2001, 9:13-7 (Exhibit 197)
	Bingaman, Adam W. et al., "Analysis of the CD40 and CD28 Pathways on Alloimmune Responses by CD4 ⁺ T Cells In Vivo," <i>Transplantation</i> , 2001, 72:1286-92 (Exhibit 198)
	Adams, Andrew B. et al., "Calcineurin Inhibitor-Free CD28 Blockade-Based Protocol Protects Allogeneic Islets in Nonhuman Primates," <i>Diabetes</i> , 2002, 51:265-70 (Exhibit 199)
	Whelchel, J. D. et al. "Evolving Strategies in Immunosuppressive Therapy: The Emory Experience," <i>Clinical Transplants</i> , 1996, J. Michael Cecka, Ph.D. and Paul I. Terasaki, Ph.D., (eds.), 249-55 (Exhibit 200)
	Ritchie, Shannon C. et al., "Regulation of Immunostimulatory Function and B7 Molecule Expression on Murine Dendritic Cells," <i>Journal of Cellular Biochemistry</i> , 1995, 21A:C1-215 (Exhibit 201)
	Alexander, Diane Z. et al., "Analysis of the Mechanisms of CTLA4-Ig Plus Bone Marrow Induced Transplantation Tolerance," <i>Journal of Cellular Biochemistry</i> , 1995, 21A:C1-301 (Exhibit 202)
	Alexander, Diane Z. et al., "CTLA4-Ig-Induced Transplantation Tolerance: Analysis of Donor Cell Chimerism," <i>Surgical Forum</i> , 1994, 45:402-4 (Exhibit 203)
	Pearson, Thomas C. et al., "CTLA4-Ig + Bone Marrow Induces Transplantation Tolerance in the Murine Model," <i>Journal of Cellular Biochemistry</i> , 1995, 21A:C1-327 (Exhibit 204)
	Lakkis, Fadi G. et al., "CTLA4Ig Induces Longterm Cardiac Allograft Survival in the Absence of Interleukin-4," <i>Journal of the American Society of Nephrology</i> , 1996, 7:1887 (Exhibit 205)

EXAMINER 	DATE CONSIDERED 2/14/05
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



RECEIVED
JAN 29 2003

FORM 1449*

INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number

DO136NP/30436.58USU1

Application Number

10/057,288

Applicant

Christian P. Larsen et al.

Filing Date

January 25, 2002

Group Art Unit

1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

M M		<ul style="list-style-type: none">• L104EA29Y (Figure 15, of the subject application) was provided to researchers at Emory University, subject to use restrictions and confidentiality by agreement, more than one year before the priority date of the subject application, i.e. May 26, 2000, for use in animal studies in the U.S.• L104EA29Y (Figure 15 of the subject application) has been the subject of human clinical trials under the direction and control of Bristol-Myers Squibb Company. L104EA29Y was given to investigators who were involved in the clinical trials subject to use restrictions and confidentiality by agreement. L104EA29Y was administered intravenously to human patients in clinical trials.<ul style="list-style-type: none">• L104EA29Y was first administered intravenously to a human patient as early as November 30, 1998 in Scotland.• L104EA29Y was first administered intravenously to a human patient as early as April 24, 1999 in the United States.• A letter dated July 9, 1998 including a report, submitted to the U.S. Food and Drug Administration in connection with an Investigational New Drug (IND) application, is enclosed as Exhibit 206.<ul style="list-style-type: none">• The letter and report are confidential and were provided confidentially, pursuant to 21 C.F.R. §20.111 or 521 C.F.R. §312.130, to the Center for Biologics Evaluation and Research at the U.S. Food and Drug Administration in connection with the Investigational New Drug Application.• The enclosed letter and report are redacted versions of what were sent to the U.S. Food and Drug Administration.• The report contained the sequence for BMS-224818 (Figure 3 at page 13 of Exhibit 206), which differs from CTLA4Ig at two amino acid residues, Leu104-Glu and Ala29-Tyr (Exhibit 206 at page 2). (Exhibit 206)
M		<ul style="list-style-type: none">• An Investigator Brochure dated January 26, 1999 is enclosed as Exhibit 207.<ul style="list-style-type: none">• The Investigator Brochure is confidential and was provided to investigators who were involved in the clinical trials and subject to confidentiality by agreement, more than one year before the priority date of the subject application, i.e. May 26, 2000.• The enclosed Investigator Brochure is a redacted version of what was sent to investigators.• The Investigator Brochure contained a text description and a schematic representation of LEA29Y (Figure 1 at page 6 of Exhibit 207), but not the sequence of L104EA29Y (Figure 15, of the subject application). (Exhibit 207)

EXAMINER

Thomas Gander

DATE CONSIDERED

1/14/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

**INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION**

(Use several sheets if necessary)

Applicant
Christian P. Larsen et al.

Filing Date
January 25, 2002

Group A
1644

RECEIVED
JUN 18 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>[Handwritten signature]</i>	6,444,792 (Exhibit 216)	09/03/02	Gray et al.			01/08/99
	5,770,197 (Exhibit 220)	06/23/98	Linsley et al.			01/22/93
	6,132,992 (Exhibit 221)	10/17/00	Ledbetter et al.			10/05/95
	5,977,318 (Exhibit 222)	11/02/99	Linsley et al.			06/07/95
	5,968,510 (Exhibit 223)	10/19/99	Linsley et al.			10/04/96
	5,993,800 (Exhibit 224)	11/30/99	Linsley et al.			06/06/95
	5,916,560 (Exhibit 225)	06/29/99	Larsen et al.			03/20/97
	5,958,403 (Exhibit 233)	09/28/99	Strom et al.			07/11/94

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 01/90122 A2 (Exhibit 208)	11/29/01	PCT				
	WO 01/54732 A1 (Exhibit 209)	08/02/01	PCT				
	WO 00/23115 (Exhibit 210)	04/27/00	PCT				
	WO 97/28267 (Exhibit 211)	08/07/97	PCT				
	WO 96/14865 (Exhibit 212)	05/23/96	PCT				
	WO 95/34320 (Exhibit 213)	12/21/95	PCT				
	WO 98/31820 (Exhibit 214)	07/23/98	PCT				
	WO 94/28912 (Exhibit 215)	12/22/94	PCT				
	WO 93/19767 (Exhibit 217)	10/14/93	PCT				
	WO 94/29436 (Exhibit 218)	12/22/94	PCT				
	WO 95/33823 (Exhibit 219)	12/14/95	PCT				
	EP 0 613 944 A2 (Exhibit 226)	09/07/94	EPO				
	EP 0 682 039 A1 (Exhibit 227)	11/15/95	EPO				
	WO 93/00431 (Exhibit 228)	01/07/93	PCT				

EXAMINER

[Handwritten signature]

DATE CONSIDERED


[Handwritten date: 2/14/05]

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)


Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)		
	Applicant Christian P. Larsen et al.	
	Filing Date January 25, 2002	Group Art Unit 1644

FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
	WO 98/56417 (Exhibit 229)	12/17/98	PCT			
	WO 95/34320 (Exhibit 230)	12/21/95	PCT			
	WO 01/92337 (Exhibit 231)	12/06/01	PCT			
	WO 98/33513 (Exhibit 232)	08/06/98	PCT			

RECEIVED
 JUN 18 2003
 TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Linsley, Peter S. et al., "Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule," <i>Science</i> , 1992, 257:792-795 (Exhibit 234)
		Morton, Phillip A. et al., "Differential Effects of CTLA-4 Substitutions on the Binding of Human CD80 (B7-1) and CD86 (B7-2)," <i>Journal of Immunology</i> , 1996, 156:1047-1054 (Exhibit 235)
		Sun, Hong et al., "Prevention of Chronic Rejection in Mouse Aortic Allografts by Combined Treatment with CTLA4-Ig and Anti-CD40 Ligand Monoclonal Antibody," <i>Transplantation</i> , 1997, 64:1838-56 (Exhibit 236)
		Souza, D. et al., "Synergistic Inhibition of Established Collagen Induced Arthritis (CIA) Through Dual Inhibition of ICAM-1 and CD40L Pathways," <i>Arthritis and Rheumatism</i> , 1999, 42:S60 (Exhibit 237)
		Blazar, Bruce R. et al., "Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 Pathways Is A Highly Effective Means of Preventing Acute Lethal Graft-Versus-Host Disease Induced by Fully Major Histocompatibility Complex-Disparate Donor Grafts," <i>Blood</i> , 1995, 85:2607-18 (Exhibit 238)
		Alegre, Maria-Luisa et al., "Immunomodulation of Transplant Rejection Using Monoclonal Antibodies and Soluble Receptors," <i>Digestive Diseases and Sciences</i> , 1995, 40:58-64 (Exhibit 239)
		Murakami, Masaaki et al., "Identification and characterization of an alternative cytotoxic T lymphocyte-associated protein 4 binding molecule on B cells," <i>Proceedings of the National Academy of Sciences USA</i> , 1995, 93:7838-7842 (Exhibit 240)
		Peach, Robert J. et al., "Both Extracellular Immunoglobulin-like Domains of CD80 Contain Residues Critical for Binding T Cell Surface Receptors CTLA-4 and CD28," <i>Journal of Biological Chemistry</i> , 1995, 270:21181-21187 (Exhibit 241)
		Fargeas, Christine et al., "Identification of Residues in the V Domain of CD80 (B7-1) Implicated in Functional Interactions with CD28 and CTLA4," <i>Journal of Experimental Medicine</i> , 1995, 182:667-675 (Exhibit 242)
		Steurer, Wolfgang et al., "Ex Vivo Coating of Islet Cell Allografts with Murin CTLA4/Fc Promotes Graft Tolerance," <i>Journal of Immunology</i> , 1995, 155:1165-1174 (Exhibit 243)
		Guo, Yong et al., "Mutational Analysis and an Alternatively Spliced Product of B7 Defines Its CD28/CTLA4-binding Site on Immunoglobulin C-like Domain," <i>Journal of Experimental Medicine</i> , 1995, 181:1345-1355 (Exhibit 244)
		Peach, Robert J. and Peter S. Linsley, "CTLA4Ig: A Novel Immunoglobulin Chimera with Immunosuppressive Properties," <i>Methods</i> , 1995, 8:116-123 (Exhibit 245)

EXAMINER 	DATE CONSIDERED 2/14/05
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

(Use several sheets if necessary)

Christian P. Larsen et al.

January 25, 2002

1644

Rattis, Frédérique-Marie et al., "Expression and function of B7-1 (CD80) and B7-2 (CD86) on human epidermal Langerhans cells," *European Journal of Immunology*, 1996, 26:449-453 (Exhibit 246)

Najafian, Nader and Mohamed H. Sayegh, "CTLA4-Ig: a novel immunosuppressive agent," *Exp. Opin. Invest. Drugs*, 2000, 9:2147-2157 (Exhibit 247)

Tan, Patrick et al., "Induction of Alloantigen-specific Hyporesponsiveness in Human T Lymphocytes by Blocking Interaction of CD28 with Its Natural Ligand B7/BB1," *Journal of Experimental Medicine*, 1993, 177:165-173 (Exhibit 248)

Turka, Laurence A. et al., "T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection *in vivo*," *Proceedings of the National Academy of Sciences USA*, 1992, 89:11102-11105 (Exhibit 249)

Scwhartz, R., "Costimulation of T Lymphocytes: The Role of CD28, CTLA-4, and B7/BB1 in Interleukin-2 Production and Immunotherapy," *Cell*, 1992, 71:1085-1088. (Exhibit 250)

RECEIVED
JUN 18 2003
TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)		
	Applicants Christian P. Larsen et al.	
	Filing Date January 25, 2002	Group Art Unit 1644

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
<i>PL</i>	WO94/01547 (Exhibit 251)	01/20/94	PCT				X
	WO95/06481 (Exhibit 252)	03/09/95	PCT				X
	WO95/28957 (Exhibit 253)	11/02/95	PCT				X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
			Bluestone, Jeffrey A., "New Perspectives of CD28-B7-Mediated T Cell Costimulation," <i>Immunity</i> , 1995, 2:555-9 (Exhibit 254)
			Bluestone, J. A., "Costimulation and its role in organ transplantation," <i>Clin. Transplantation</i> , 1996, 10:104-9 (Exhibit 255)
			Chen, Fang-An et al., "Human Antibody Response in Human Peripheral Blood Leukocyte/Severe Combined Immunodeficient Chimeric Model is Dependent on B and T Cell Costimulation via CD40/CD40 Ligand," <i>Journal of Immunology</i> , 1995, 155:2833-40 (Exhibit 256)
			Durie, Fiona H. et al., "Prevention of Collagen-Induced Arthritis with an Antibody to gp39, the Ligand for CD40," <i>Science</i> , 1993, 261:1328-30 (Exhibit 257)
			Durie, Fiona H. et al., "Antibody to the Ligand of CD40, gp39, Blocks the Occurrence of the Acute and Chronic Forms of Graft-vs-Host Disease," <i>Journal of Clinical Investigation</i> , 1994, 94:1333-8 (Exhibit 258)
			Griggs, Nathan et al., "Contribution of CD28/CTLA4/B7 and gp39/CD40 Costimulation Pathways in Clonal Expansion and Functional Acquisition of Self Reactive T Cells," <i>Journal of Cellular Biochemistry</i> , 1995, Supplement, p. 141, C2-427 (Exhibit 259)
			Jenkins, Marc K. et al., "CD28 Delivers a Costimulatory Signal Involved in Antigen-Specific IL-2 Production by Human T Cells," <i>Journal of Immunology</i> , 1991, 147:2461-6 (Exhibit 260)
			Lenschow, Deborah J. et al., "Inhibition of Transplant Rejection Following Treatment with Anti-B7-2 and Anti-B7-1 Antibodies," <i>Transplantation</i> , 1995, 60:1171-8 (Exhibit 261)
<i>PL</i>			Rossini, Aldo A. et al., "Induction of Immunological Tolerance to Islet Allografts," <i>Cell Transplantation</i> , 1996, 5:49-52 (Exhibit 262)

EXAMINER <i>Phurp Gambel</i>	DATE CONSIDERED <i>2/14/05</i>
---------------------------------	-----------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

(Use several sheets if necessary)

Christian P. Larsen et al.

January 25, 2002

1644

Roy, Meenakshi et al., "Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune response," *European Journal of Immunology*, 1995, 25:596-603 (Exhibit 263)

Schaub, M. et al., "Synergistic effect of CD40L/CD40 and CD28/B7 Blockade in murine EAE," *Journal of Allergy and Clinical Immunology*, 1997, 99:5206, Abstract 843 (Exhibit 264)

Tang, Aimin et al., "Suppression of Murine Allergic Contact Dermatitis by CTLA4lg: Tolerance Induction of Th2 Responses Requires Additional Blockade of CD40-Ligand," *Journal of Immunology*, 1996, 157:117-25 (Exhibit 265)

PAUL P. GAMBRO

2/15/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE